ArticleDiabetes therapy : research, treatment and education of diabetes and related disorders2018
Comorbidity Type and Health Care Costs in Type 2 Diabetes: A Retrospective Claims Database Analysis.
Article in Diabetes therapy : research, treatment and education of diabetes and related disorders, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Global prevalence of multimorbidity among people living with type 2 diabetes: a systematic review and meta-analysis.BMC public health · 2025Pooled it
- Costs of Comorbidities and Complications Associated with Type 2 Diabetes: A Retrospective, Cohort Study.Advances in therapy · 2026Article
- The association between liver function tests abnormalities and type 2 diabetes mellitus patients in Saudi Arabia: a cross-sectional study.Frontiers in clinical diabetes and healthcare · 2025Article
- A Problem in NIH and Federally Funded Prostate Cancer Interventional Clinical Trials.Journal of racial and ethnic health disparities · 2024Article
- Machine Learning Approach with Harmonized Multinational Datasets for Enhanced Prediction of Hypothyroidism in Patients with Type 2 Diabetes.Diagnostics (Basel, Switzerland) · 2024Article
- Multimorbidity healthcare expenditure in Belgium: a 4-year analysis (COMORB study).Health research policy and systems · 2024Article
- Sociodemographic disparities in GLP-1RA and SGLT2i use among US adults with type 2 diabetes: NHANES 2005-March 2020.Current medical research and opinion · 2024Article
- An Economic Evaluation of the Relationship Between Glycemic Control and Total Healthcare Costs for Adults with Type 2 Diabetes: Retrospective Cohort Study.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2024Article
- Prevalence and co-prevalence of comorbidities among Chinese adult patients with type 2 diabetes mellitus: a cross-sectional, multicenter, retrospective, observational study based on 3B study database.Frontiers in endocrinology · 2024Observational
- Factors associated with diabetes concordant comorbidities among adult diabetic patients in Central Ethiopia: a cross-sectional study.Frontiers in clinical diabetes and healthcare · 2023Article
- Healthcare Costs and Health-Related Quality of Life in Older Multimorbid Patients After Hospitalization.Health services insights · 2023Article
- An Economic Impact Model for Estimating the Value to Health Systems of a Digital Intervention for Diabetes Primary Care: Development and Usefulness Study.JMIR formative research · 2022Article
- Hospital treatment costs associated with incident complications in patients with type 2 diabetes-real-world study based on electronic patient information systems.BMC health services research · 2022Article
- In-patient care trends in peripheral artery disease in the German healthcare system over the past decade.European radiology · 2022Article
- Consultation rates in people with type 2 diabetes with and without vascular complications: a retrospective analysis of 141,328 adults in England.Cardiovascular diabetology · 2022Observational
- Value of Patient-Centered Glycemic Control in Patients with Type 2 Diabetes.Current diabetes reports · 2021Review
- Multimorbidity and achievement of treatment goals among patients with type 2 diabetes: a primary care, real-world study.BMC health services research · 2021Article
- Comparison of Communication Channels for Large-Scale Type 2 Diabetes Risk Screening and Intervention Recruitment: Empirical Study.JMIR diabetes · 2021Article
- Isoprenoid Derivatives of Lysophosphatidylcholines Enhance Insulin and GLP-1 Secretion through Lipid-Binding GPCRs.International journal of molecular sciences · 2021Article
- Occurrence of comorbidities in newly diagnosed type 2 diabetes patients and their impact after 11 years' follow-up.Scientific reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPrevious studies suggest that the type and combination of comorbidities may impact diabetes care, but their cost implications are less clear. This study characterized how diabetes patients' health care utilization and costs may vary according to comorbidity type classified on the basis of the Piette and Kerr framework.
methodsWe conducted a retrospective observational study of privately insured US adults newly diagnosed with type 2 diabetes (n = 138,466) using the 2014-2016 Optum Clinformatics
resultsMost type 2 diabetes patients had discordant conditions only (27%), dominant conditions (25%), or both concordant and discordant conditions (24%); 7% had concordant conditions only. In adjusted analyses, comorbidities were significantly associated with higher health care costs (p < 0.0001) and the magnitude of the association varied with comorbidity type. Diabetes patients with dominant comorbidities incurred substantially higher costs ($38,168) compared with individuals with both concordant and discordant conditions ($20,401), discordant conditions only ($9173), concordant conditions only ($9000), and no comorbidities ($3365). More than half of the total costs in our sample (53%) were attributable to 25% of diabetes patients who had dominant comorbidities.
conclusionsDiabetes patients with both concordant and discordant conditions and with clinically dominant conditions incurred substantially higher health costs than other diabetes patients. Our findings suggest that diabetes management programs must explicitly address concordant, discordant, and dominant conditions because patients may have distinctly different health care needs and utilization patterns depending on their comorbidity profiles. The Piette and Kerr framework may serve as a screening tool to identify high-need, high-cost diabetes patients and suggest targets for tailored interventions.
fundingSanofi.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.